title: Chorioretinal Lesions in a Case of Melanoma-Associated Retinopathy Treated With Pembrolizumab.
abstract: OBJECTIVE
  In recent years, the treatment of patients with advanced cutaneous melanoma has undergone substantial changes. Patients can now be offered treatment with immune checkpoint inhibitors, which are capable of increasing patient survival. However, these new treatments are associated with immune-related adverse effects that can involve different organ systems, including the eye.
  
  
  METHODS
  We describe the case of a patient who received a diagnosis of metastatic cutaneous melanoma and developed melanoma-associated retinopathy with unanticipated fundus findings while receiving treatment with the immune checkpoint inhibitor pembrolizumab. Chorioretinal scars with pigment accumulations developed in the retinal periphery in both eyes.
  
  
  CONCLUSIONS
  Immune checkpoint inhibitors, which are now being used more commonly for patients with advanced stages of melanoma, can exacerbate autoimmune diseases in patients with underlying clinical or latent autoimmunity. Clinicians should be aware of atypical eye findings, including chorioretinal scars.
authors.affiliation: Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois2Department of Ophthalmology, Medical University of Vienna, Vienna, Austria.
authors.forename: Philipp
authors.initials: P
authors.lastname: Roberts
authors.affiliation: The Chicago Lighthouse for People Who Are Blind or Visually Impaired, Chicago, Illinois.
authors.forename: Gerald A
authors.initials: GA
authors.lastname: Fishman
authors.affiliation: Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
authors.forename: Komal
authors.initials: K
authors.lastname: Joshi
authors.affiliation: Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
authors.forename: Lee M
authors.initials: LM
authors.lastname: Jampol
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005134:Eye Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary; D005500:Follow-Up Studies; D006801:Humans; D008545:Melanoma / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D009362:Neoplasm Metastasis; D012164:Retinal Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D012878:Skin Neoplasms; D000096142:Cutaneous Malignant Melanoma
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C582435:pembrolizumab